Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nu-3 Gel Safety in Chronic Diabetic Foot Ulcers
NCT05276401Phase 2Terminated
- Sponsor
- Lakewood-Amedex Biotherapeutics
- Start
- Mar 2022
- Primary completion
- May 2022
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of bisphosphocin nu-3 in diabetic foot ulcer (DFU), sponsored by Lakewood-Amedex Biotherapeutics. Started Mar 2022; status: terminated.
02
Drugs
bisphosphocin nu-3
03
Conditions
diabetic foot ulcer (DFU)
Beyond the preview
Go deeper on NCT05276401.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05276401.